Email Alert | RSS

北京大学学报（医学版） ›› 2018, Vol. 50 ›› Issue (6): 975-980. doi: 10.19723/j.issn.1671-167X.2018.06.006

• 论著 • 上一篇    下一篇

可溶性白细胞介素2受体α链的检测与类风湿关节炎疾病活动性评估

胥佳佳1,王燕1,△(),孙贺1,贾汝琳2,张学武1,△(),孟洋1,任丽丽1,孙晓麟2   

  1. 1. 郑州大学第五附属医院风湿免疫科, 郑州　450000
    2. 北京大学人民医院风湿免疫科, 北京 100044
  • 收稿日期:2018-07-10 出版日期:2018-12-18 发布日期:2018-12-18
  • 通讯作者: 王燕,张学武 E-mail:wangyanh_1963@163.com;xuewu@sohu.com
  • 基金资助:
    国家自然科学基金(81471601)

Clinical significance of detection of soluble interleukin 2 receptor alpha chain in the assessment of rheumatoid arthritis disease activity

Jia jia XU1,Yan WANG1,△(),He SUN1,Ru lin JIA2,Xue wu ZHANG1,△(),Yang MENG1,Li li REN1,Xiao lin SUN2   

  1. 1. Department of Rheumatology and Immunology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
    2. Department of Rheumatology and Immunology,Peking University People’s Hospital,Beijing 100044, China
  • Received:2018-07-10 Online:2018-12-18 Published:2018-12-18
  • Contact: Yan WANG,Xue wu ZHANG E-mail:wangyanh_1963@163.com;xuewu@sohu.com
  • Supported by:
    Supported by the National Natural Science Foundation of China(81471601)

RICH HTML

 32   

PDF (PC)

241

摘要：

目的: 评价血清可溶性白细胞介素2受体α链(sIL-2Rα、sCD25)对类风湿关节炎(rheumatoid arthritis,RA)活动度评估的临床意义。方法: 收集RA患者血清108例,RA关节液标本40例,骨关节炎(osteoarthritis,OA)患者血清39例,健康人血清50例,采用酶联免疫吸附(ELISA)检测各组血清、以及RA患者关节液中sCD25浓度,并记录RA患者的各项临床表现和实验室指标,分析其与血清sCD25浓度水平的相关性。结果: RA组血清sCD25(质量)浓度为(2 886±1 333) ng/L,OA组血清sCD25浓度为(2 090±718) ng/L,健康对照组血清sCD25浓度为(1 768±753) ng/L;RA患者的血清sCD25水平显著高于疾病对照组和健康对照组(P< 0.001);血清中sCD25水平与红细胞沉降率(r=0.321,P = 0.001)、C-反应蛋白(r=0.446,P<0.001)、DAS28评分(r=0.324, P<0.001)、关节压痛计数(r = 0.203,P =0.024)、D-二聚体(D-dimer)水平(r=0.383,P<0.001)、年龄(r = 0.24,P = 0.007)、总IgG(r = 0.207,P = 0.028)、类风湿因子IgG(r = 0.345,P = 0.034)呈正相关,与病程呈负相关(r = -0.206,P = 0.021);在RA患者中,低疾病活动度组血清ESR、CRP和sCD25阳性率分别为14.3%(2例),14.3%(2例),71.4%(10例);中疾病活动度组血清ESR、CRP和sCD25阳性率分别为94.2%(49例)、82.7%(43例)和86.5%(45例);高疾病活动度组血清ESR、CRP和sCD25阳性率分别为100%(42例)、95.2%(40例)和90.5%(38例);有36例ESR和/或CRP为阴性(约33.3%),在这36例中有17例(约47.2%)血清sCD5水平升高,并且其中14例(约82.4%)DAS28评分高于3.2。结论: 血清sCD25水平与RA活动性密切相关,表明sCD25可能参与了RA的炎症过程,并有望成为RA患者的一种新的炎症指标;血清sCD25的检测在RA处于病情活动期,但ESR和/或CRP为阴性时更有意义。

关键词: 类风湿关节炎,活动性, 可溶性白细胞介素-2受体α链;, 血清sCD25, 血沉, C-反应蛋白

Abstract:

Objective: To evaluate soluble interleukin-2 receptor alpha chain (sIL-2Rα, sCD25) in serum for the determination of rheumatoid arthritis (RA) activity.Methods:Peripheral blood was collected from 108 patients with RA, 39 patients with osteoarthritis (OA) and 50 healthy control subjects, and synovial fluids were from 40 patients with RA. The sera from the patients with RA, the disease control group (osteoarthritis), the healthy control group, and the synovial fluids of the RA patients were detected by enzyme-linked immunosorbent assay (ELISA).The clinical manifestations and laboratory parameters of the patients with RA were recorded and the correlation with the serum sCD25 level was analyzed.Results:The serum sCD25 concentration in RA group was (2 886±1 333) ng/L, the serum sCD25 concentration in OA group was (2 090±718) ng/L, and the serum sCD25 concentration in healthy group was (1 768±753) ng/L. The serum sCD25 level in the patients with RA was significantly higher than that in the disease controls and healthy controls (P<0.001). Sensitivity of serum sCD25 in the diagnosis of RA was 66.1% and specificity was 83.0%;serum sCD25 levels and erythrocyte sedimentation rate (r = 0.321, P = 0.001), C-reactive protein (r=0.446, P<0.001), DAS28 score (r = 0.324, P<0.001), joint tenderness count (r=0.203, P=0.024), D-dimer levels (r=0.383, P<0.001), age (r=0.24, P=0.007), IgG (r=0.207, P=0.028), HRF-IgG (r=0.345, P=0.034) showed a significant positive correlation, and disease duration (r=-0.206, P=0.021) showed a negative correlation with sCD25;In patients with rheumatoid arthritis, the positive rates of serum ESR, CRP, and sCD25 were 14.3% (2 cases), 14.3% (2 cases), and 71.4% (10 cases) in the low disease activity group. The positive rates of serum ESR, CRP and sCD25 in the moderate disease activity group were 94.2% (49 cases), 82.7% (43 cases), and 86.5% (45 cases). The positive rates of serum ESR, CRP, and sCD25 in the high disease activity group were 100% (42 cases), 95.2% (40 cases), and 90.5% (38 cases);36 cases of ESR and/or CRP were negative (about 33.3%) in 108 patients, serum sCD5 levels of 17 cases in these 36 cases (about 47.2%)increased, of which 14 cases (about 82.4%) had a DAS28 score higher than 3.2.Conclusion:The serum sCD25 has a high specificity for diagnosis of RA and a poor sensitivity. The serum level is closely related to the activity of RA, indicating that sCD25 may be involved in the inflammatory process of RA and may become a new inflammatory marker of RA.It is more meaningful for detection of serum sCD25 when RA is active, but ESR and/or CRP is negative.

Key words: Rheumatoid arthritis,activity, Interleukin 2 receptor α chain;, Sera sCD25, Erythrocyte sedimentation rate, C-reactive protein

中图分类号: 

  • R593.22

图1

RA患者、OA患者及健康人血清sCD25水平及部分RA患者关节液sCD25水平分析"

表1

RA患者的血清sCD25水平与实验室指标的相关性"

Characteristics sCD25 in peripheral blood/(ng/L)
r P
Age/years 0.24 0.007*
Duration/years -0.206 0.021*
Tender joints, n 0.203 0.024*
Swollen joints, n 0.156 0.083
RF/(IU/mL) 0.110 0.248
ESR/(mm/h) 0.321 0.001*
CRP/(mg/L) 0.446 <0.001*
ACPA/(IU/mL) 0.043 0.659
RF-IgG/(IU/mL) 0.345 0.034*
GPI/(mg/L) 0.127 0.375
IgG/(g/L) 0.207 0.028*
IgA/(g/L) 0.159 0.092
IgM/(g/L) 0.069 0.467
C3/(g/L) 0.083 0.384
C4/(g/L) 0.059 0.537
ASO/(IU/mL) 0.048 0.614
D-dimer/(mg/L) 0.383 <0.001*
WBC/(×109/L) 0.214 0.017*
Neu/% 0.262 0.003*
DAS28 0.324 <0.001*

表2

低、中、高疾病活动度组的DAS28、ESR、CRP和sCD25的分布情况(x-±s )"

Items LDA(n=14) MDA(n=52) HDA(n=42)
DAS28 3.11±0.05 4.46±0.51 5.67±0.32
ESR/(mm/h)* 12.50±5.58 32.62±23.18 62.19±28.45
CRP/(mg/L)* 17.00±2.05 19.65±25.16 50.26±38.16
sCD25/(ng/L)* 2 592±1 380 2 904±1 821 3 351±1 974

图2

不同疾病活动度中的ESR、CRP和sCD25的阳性率比较"

[1] Calabresi E, Petrelli F, Bonifacio AF , et al. One year in review 2018: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2018,36(2):175-184.
[2] Kumar LD, Karthik R, Gayathri N , et al. Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis[J]. Biomed Pharmacother, 2016,79:52-61.
doi: 10.1016/j.biopha.2016.02.001 pmid: 27044812
[3] Chavele KM, Ehrenstein MR . Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis[J]. FEBS Lett, 2011,585(23):3603-3610.
doi: 10.1016/j.febslet.2011.07.043 pmid: 21827750
[4] Boyman O, Kolios AG, Raeber ME . Modulation of T cell responses by IL-2 and IL-2 complexes[J]. Clin Exp Rheumatol, 2015,33(4 Suppl 92):S54-S57.
pmid: 26457438
[5] Howell MD, Diveley JP, Lundeen KA , et al. Limited T-cell receptor beta-chain heterogeneity among interleukin 2 receptor-positive synovial T cells suggests a role for superantigen in rheumatoid arthritis[J]. Proc Natl Acad Sci USA, 1991,88(23):10921-10925.
doi: 10.1073/pnas.88.23.10921
[6] Liao W, Lin JX, Leonard WJ . Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy[J]. Immunity, 2013,38(1):13-25.
doi: 10.1016/j.immuni.2013.01.004 pmid: 3610532
[7] Setoguchi R, Hori S, Takahashi T , et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization[J]. J Exp Med, 2005,201(5):723-735.
doi: 10.1084/jem.20041982
[8] Fulop T, Larbi A, Douziech N , et al. Cytokine receptor signalling and aging[J]. Mech Ageing Dev, 2006,127(6):526-537.
doi: 10.1016/j.mad.2006.01.025 pmid: 16530252
[9] Chrobak L . Clinical significance of soluble interleukin-2 receptor[J]. Acta Medica (Hradec Kralove), 1996,39(1):3-6.
pmid: 9106384
[10] Murakami S . Soluble interleukin-2 receptor in cancer[J]. Front Biosci, 2004,9:3085-3090.
doi: 10.2741/1461 pmid: 15353339
[11] Britsemmer K, Ursum J, Gerritsen M , et al. Validation of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria[J]. Ann Rheum Dis, 2011,70(8):1468-1470.
doi: 10.1136/ard.2010.148619 pmid: 21586440
[12] Zhang W, Doherty M, Peat G , et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis[J]. Ann Rheum Dis, 2010,69(3):483-489.
doi: 10.1136/ard.2009.113100 pmid: 19762361
[13] Schett G, Gravallese E . Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment[J]. Nat Rev Rheumatol, 2012,8(11):656-664.
doi: 10.1038/nrrheum.2012.153 pmid: 23007741
[14] Lee YH, Bae SC, Song GG . Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis[J]. Z Rheumatol, 2015,74(10):911-918.
doi: 10.1007/s00393-016-0134-y pmid: 27312463
[15] Avouac J, Gossec L, Dougados M . Diagnostic and predictive value of anti-cyclic citrullinated proteinantibodies in rheumatoid arthritis: a systematic literature review[J]. Ann Rheum Dis, 2006,65(7):845-851.
[16] Sun J, Zhang Y, Liu L , et al. Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis[J]. Clin Exp Rheumatol, 2014,32(1):11-21.
doi: 10.1016/j.rbre.2014.02.013 pmid: 24050751
[17] Tak PP, Bresnihan B . The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis[J]. Arthritis Rheum, 2000,43(12):2619-2633.
doi: 10.1002/1529-0131(200012)43:123.0.CO;2-V pmid: 11145019
[18] Weyand CM, Goronzy JJ . Immunometabolism in early and late stages of rheumatoid arthritis[J]. Nat Rev Rheumatol, 2017,13(5):291-301.
doi: 10.1038/nrrheum.2017.49 pmid: 28360422
[19] Malmstrom V, Catrina AI, Klareskog L . The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting[J]. Nat Rev Immunol, 2017,17(1):60-75.
doi: 10.1038/nri.2016.124 pmid: 27916980
[20] Dlouhy I, Filella X, Rovira J , et al. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma[J]. Leuk Res, 2017,59:20-25.
doi: 10.1016/j.leukres.2017.05.014
[21] Akiyama M, Sasaki T, Kaneko Y , et al. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren’s syndrome adults from a defined population[J]. Clin Exp Rheumatol, 2018,112(36 Suppl 3):157-164.
pmid: 29465360
[22] Gundlach E, Hoffmann M M, Prasse A , et al. Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis[J]. PLoS One, 2016,11(1):e147258.
doi: 10.1371/journal.pone.0147258 pmid: 4723126
[23] Nukui A, Masuda A, Abe H , et al. Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy[J]. BMC Cancer, 2017,17(1):372.
doi: 10.1186/s12885-017-3369-3 pmid: 28545581
[24] Spadaro A, Taccari E, Riccieri V , et al. Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis[J]. Rev Rhum Engl Ed, 1997,64(2):89-94.
doi: 10.1016/S0950-3579(97)80028-3 pmid: 9085442
[25] Knevel R, de Rooy DP, Zhernakova A , et al. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis[J]. Arthritis Rheum, 2013,65(7):1684-1693.
doi: 10.1002/art.37938
[26] van Steenbergen HW, van Nies JA, Ruyssen-Witrand A , et al. IL2RA is associated with persistence of rheumatoid arthritis[J]. Arthritis Res Ther, 2015,17:244.
doi: 10.1186/s13075-015-0739-6 pmid: 4563834
[27] Turka LA, Walsh PT . IL-2 signaling and CD4+CD25+Foxp3+regulatory T cells[J]. Front Biosci, 2008,13:1440-1446.
doi: 10.2741/2773 pmid: 17981641
[28] von Spee-Mayer C, Siegert E, Abdirama D , et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus[J]. Ann Rheum Dis, 2016,75(7):1407-1415.
doi: 10.1136/annrheumdis-2015-207776 pmid: 26324847
[29] Matsuoka K, Koreth J, Kim HT , et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease[J]. Sci Transl Med, 2013,5(179):143r-179r.
doi: 10.1126/scitranslmed.3005265 pmid: 368651795284151236538681511
[30] Gaujoux-Viala C, Mouterde G, Baillet A , et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI[J]. Joint Bone Spine, 2012,79(2):149-155.
doi: 10.1016/j.jbspin.2011.04.008
[31] Aletaha D, Nell VP, Stamm T , et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score[J]. Arthritis Res Ther, 2005,7(4):R796-R806.
doi: 10.1186/ar1740 pmid: 1175030
[32] Stojan G, Fang H, Magder L , et al. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity[J]. Lupus, 2013,22(8):827-834.
doi: 10.1177/0961203313492578
[33] Orr C K, Najm A, Young F , et al. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis[J]. Front Med (Lausanne), 2018,5:185.
[1] 刘梦珂,王露辰,胡凡磊. 血清基质金属蛋白酶3水平与早期类风湿关节炎病情评估[J]. 北京大学学报（医学版）, 2018, 50(6): 981-985.
[2] 陈智滨 ，林琴 ， 马长华， 刘凯宁 ，孟焕新. 自然沉降法分离抗凝全血建立生物样本库的特点[J]. 北京大学学报（医学版）, 2014, 46(1): 111-114.
[3] 张春雨, 刘丽丽, 廖莹, 杜军保, 金红芳. 血浆前白蛋白联合C-反应蛋白对川崎病患儿冠状动脉病变的预测[J]. 北京大学学报（医学版）, 2013, 45(2): 207-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报（医学版）, 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报（医学版）, 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报（医学版）, 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报（医学版）, 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报（医学版）, 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报（医学版）, 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报（医学版）, 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报（医学版）, 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报（医学版）, 2007, 39(4): 346 -350 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部